A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
暂无分享,去创建一个
T. Meyer | J. Graham | P. Ross | D. Palmer | Yuk Ting Ma | L. Fartoux | A. Deptała | M. Studeny | D. Schnell | M. Peck‐Radosavljevic | J. Hocke | A. Loembé | P. Ross | Y. T. Ma